
Vigil Neuroscience (VIGL) Stock Forecast & Price Target
Vigil Neuroscience (VIGL) Analyst Ratings
Bulls say
Vigil Neuroscience Inc is a clinical-stage biotechnology company focused on developing therapeutics for neurodegenerative diseases, particularly through its small molecule TREM2 agonist program, VG-3927, which has exhibited a significant dose-dependent reduction in sTREM2 and shows promise for once-daily dosing. The company's strategic partnership with Sanofi underscores its credibility and potential for commercialization, as Sanofi has secured exclusive negotiation rights for the TREM2 agonist program. With a currently negative enterprise value of $25 million and the robust Phase I data supporting its therapeutic programs, there is a perceived significant upside potential for Vigil's stock, especially with any evidence of slowing disease progression in patients.
Bears say
Vigil Neuroscience has faced a notable decline in its stock price, evidenced by a 26% decrease since the ALEC TREM2 data readout, compounded by a reported net loss of $23.8 million, translating to a GAAP EPS of $(0.57). Additionally, the company has increased its valuation discount rate to 35%, resulting in a reduced target price of $13, significantly lower than the previous target of $24, further highlighting investor concerns. Coupled with the potential risks related to failure in commercial execution and exceeding market expectations, the financial outlook for Vigil Neuroscience appears increasingly negative.
This aggregate rating is based on analysts' research of Vigil Neuroscience and is not a guaranteed prediction by Public.com or investment advice.
Vigil Neuroscience (VIGL) Analyst Forecast & Price Prediction
Start investing in Vigil Neuroscience (VIGL)
Order type
Buy in
Order amount
Est. shares
0 shares